Stroke and aspirin non-responder patients: Relation with hypertension and platelet response to adenosine diphosphate

Platelets

Volumn 20, Issue 7, 2009, Pages 471-477

  Godeneche, G ^a   Sorel, N ^b   Ragot, S ^c   Chomel, J C ^b   Neau, J P ^a   MacChi, L ^b,d  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b Service d'Hmatologie et Oncologie Biologique   (France)

^c INSERM   (France)

^d UNIVERSITÉ DE POITIERS   (France)

Author keywords

Adenosine diphosphate; Aspirin non response; Hypertension; PFA 100 ; Platelet glycoprotein; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; ALPHA2 INTEGRIN; COLLAGEN; GLYCOPROTEIN; GLYCOPROTEIN IIIA; GLYCOPROTEIN VI; PURINERGIC P2Y12 RECEPTOR;

AGED; ANALYZER; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENETIC TRAIT; GENOTYPE; HUMAN; HYPERTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUTATION; PREDICTION; PREVALENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE; THROMBOCYTE; THROMBOCYTE FUNCTION;

ADENOSINE DIPHOSPHATE; AGED; ASPIRIN; BLOOD PLATELETS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; STROKE;

TETRA;

EID: 70350492570     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537100903171404     Document Type: Article

References (34)

1. Antithrombotic Trialist' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Goldwin J, Peto R, Buring J, Hennekens G, Kearney P, Meade T, et al. Stroke and aspirin non-responder patients: Relation with hypertension and platelet response to adenosine diphosphate. Lancet 2009;373:1849-1860.
2. Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: A meta-analysis. Am J Med 2008;121:43-49.
3. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006;367:606-617.
4. Macchi L, Christiaens L, Brabant S, Sorel N, Allal J, Mauco G, Brizard A. Resistance to aspirin in vitro is associated with increase platelet sensitivity to adenosine diphosphate. Thromb Res 2002;107:45-49.
5. Macchi L, Petit E, Brizard A, Gil R, Neau JP. Aspirin resistance in vitro and hypertension in stroke patients. J Thromb Haemost 2004;2:2051-2053.
6. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE III; TOAST Investigator. Classification of subtypes of acute ischaemic stroke. Definition for use in a multicenter clinical trial. Stroke 1993;24:35-41.
7. Newman PJ, Derbes RS, Aster RH. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/ proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest 1989;83:1778-1781.
8. Kunicki TJ, Kritzik M, Annis DS, Nugent DJ. Hereditary variation in platelet integrin alpha 2 beta 1 density is associated with two silent polymorphisms in the alpha 2 gene coding sequence. Blood 1997;89:1939-1943.
9. Croft SA, Samani NJ, Teare MD, Hampton KK, Steeds RP, Channer KS, Daly ME. Novel platelet membrane glycoprotein VI dimorphism is a risk factor for myocardial infarction. Circulation 2001;104:1459-1463.
10. Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M, Gaussem P. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003;108:989-995.
11. Ye S, Dhillon S, Ke X, Collins AR, Day IN. An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acid Res 2001;29:E88-8.
12. Ji L, Pan S, Marti-Jaun J, Hanseler E, Rentsch K, Hersberger M. Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in mainland Chinese. Clin Chem 2002;48:983-988.
13. Hovens MCM, Snoep JD, Eikenboom JCJ, Van der Bom JG, Mertens BJA, Huisman MV. Prevalence of persistent platelet reactivity despite use of aspirin: A systematic review. Am Heart J 2007;153:175-181.
14. Harrison P, Segal H, Blasbery K, Furtado C, Silver L, Rothwell PM. Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 pointof- care platelet function tests with optical aggregometry. Stroke 2005;36:1001-1005.
15. Alberts MJ, Bergman DL, Molner E, Jovanovic BD, Ushiwata I, Teruya J. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 2004;35:175-178.
16. Berrouschot J, Schwetlick B, von Twickel G, Fischer C, Uhlemann H, Siegemund T, Siegemund A, Roessler A. Aspirin resistance in secondary stroke prevention. Acta Neurol Scand 2006;1:31-35.
17. Helgason CM, Tortorice KL, Winkler SR, Penney DW, Schuler JJ, McClelland TJ, Brace LD. Aspirin response and failure in cerebral infarction. Stroke 1993;24:345-350.
18. Blann AD, Lanza F, Galajda P, Gurney D, Moog S, Cazenave JP, Lip GYH. Increased platelet glycoprotein V levels in patients with coronary and peripheral atherosclerosis. The influence of aspirin and cigarette smoking. Thromb Haemost 2001;86:777-783.
19. Linden MD, Furman MI, Frelinger III AL, Fox ML, Barnard MR, Li Y, Przyklenk K, Michelson AD. Indices of platelets activation and the stability of coronary artery disease. J Thromb Haemost 2007;5:761-765.
20. Reny JL, De Moerloose P, Dauzat M, Fontana P. Use of the PFA-100TM closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2008;6: 444-450.
21. Lominadze D, Schuschke DA, Joshua IG, Dean WL. Increased ability of erythrocytes to aggregate in spontaneously hypertensive rats. Clin Exp Hypertens 2002;24:397-406.
22. Kearnet-Schwartz A, Virion JM, Stoltz JF, Drouin P, Zannad F. Haemorheological disturbances in hypertensive type 2 patients: Influence of hypertensive therapy. Fundam Clin Pharmacol 2007;21:387-396.
23. Valles J, Santos MT, Aznar J, Martinez M, Moscardo A, Pinon M, Broekman MJ, Marcus AJ. Platelet-erythrocyte interactions enhance aIIab3 integrin receptor activation and P-selectin expression during platelet recruitment: Down regulation by aspirin ex vivo. Blood 2002;99:3978-3984.
24. Santos MT, Valles J, Marcus AJ, Safier LB, Broekman MJ, Islam N, Ullman HL, Eiroa AM, Aznar J. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. J Clin Invest 1991;87:571-580.
25. Santos MT, Valles J, Aznar J, Marcus AJ, Broekman MJ, Safier LB. Prothrombotic effects of erythrocytes on platelet reactivity: Reduction by aspirin. Circulation 1997;95:63-68.
26. Valles J, Santos MT, Aznar J, Osa A, Lago A, Cosin J, Sanchez E, Broekman MJ, Marcus AJ. Erythrocytes promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: The effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 1998;97:350-355.
27. Santos MT, Valles J, Aznar J, Lago A, Sanchez E, Cosin J, Moscardo A, Pinon M, Broekman MJ, Marcus AJ. Aspirin therapy for inhibition of platelet reactivity in the presence of erythrocytes in patients with vascular disease. J Lab Clin Med 2006;147:220-227.
28. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Cavallari U, Trabetti E, Sabate M, Jimenez-Quevedo P, Hernandez R, Moreno R, et al. Lack of association between P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb Res 2005;116:491-497.
29. Macchi L, Christiaens L, Brabant S, Sorel N, Ragot S, Allal J, Mauco G, Brizard A. Resistance in vitro to low dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T (GP Ia-IIa) and C-5T Kozak (GP Iba) polymorphisms. J Am Coll Cardiol 2003;42:1115-1119.
30. Pamukcu B, Oflaz H, Nisanci Y. The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis. Am J Cardiol 2005;149:675-680.
31. Lepäntalo A, Mikkelsson J, Resendiz JC, Viiri L, Backman JT, Kankuri E, Karhunen PJ, Lassila R. Polymorphism of COX-1 and GP VI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb Haemost 2006;95:253-259.
32. Bigalke B, Lindemann S, Ehlers R, Seizer P, Daub K, Langer H, Schonberger T, Kremmer E, Siegel-Axel D, May AE, et al. Expression of platelet collagen receptor glycoprotein VI is associated with acute coronary syndrome. Eur Heart J 2006;27:2165-2169.
33. Ollikainen E, Mikkelsson J, Perola M, Penttilä A, Karkhunen PJ. Platelet membrane collagen receptor glycoprotein VI polymorphism is associated with coronary thrombosis and fatal myocardial infraction in middle-aged men. Atherosclerosis 2004;176:95-99.
34. Heemskerk JW, Siljander P, Vuist WM, Breikers G, Reutelingsperger CPM, Barnes MJ, Knight CG, Lassila R, Farndale RW. Function of glycoprotein VI and integrin a2b1 in the procoagulant response of single, collagen adherent platelet. Thromb Haemost 1999;81:782-792.